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1344Results: Combinations of TH1/TH2/TH17 cytokine profiles in
patients with CRSwNP varied considerably between regions.
CRSwNP tissues from patients from Benelux, Berlin, Adelaide,
and Tochigi were TH2 biased, whereas those from Beijing
mainly demonstrated TH2/TH1/TH17 mixed patterns, and
patients from Chengdu showed an even lower TH2 expression.
Concentrations of IL-8 and tissue total IgE in patients with
CRSwNP were significantly higher than those in control
subjects in all regions. More than 50% of patients with
CRSwNP in Benelux, Berlin, Adelaide, and Tochigi showed a
predominantly eosinophilic endotype compared with less than
30% of patients in Beijing and Chengdu. SE-specific IgE was
found in significantly greater numbers in patients with CRSwNP
from Benelux, Adelaide, and Tochigi and significantly lower
numbers in patients from Beijing and Chengdu. Moreover, the
TH1/TH2/TH17 cytokine profiles in patients with CRSsNP
showed diversity among the 6 regions.
Conclusion: TH cytokine levels, eosinophilic/neutrophilic
patterns, and SE-specific IgE expressions show extreme
diversity among patients with CRS from Europe, Asia, and
Oceania. (J Allergy Clin Immunol 2016;138:1344-53.)
Key words: TH cytokines, IgE, ECP, chronic rhinosinusitis, pheno-
type, endotype, Europe, Asia, Australia
Discuss this article on the JACI Journal Club blog: www.jaci-
online.blogspot.com.Chronic rhinosinusitis (CRS), a chronic inflammatory disease
of the paranasal sinuses, is prevalent in 7% to 27% of adults in
European countries, 14% in the United States, and 2.1% to 8% in
China.1-4 CRS is classified into 2 phenotypes, chronic rhinosinu-
sitis without nasal polyps (CRSsNP) and chronic rhinosinusitis
with nasal polyps (CRSwNP), according to US and European
clinical guidelines.1,5
Evidence from several studies indicates that there are distinct
immunologic mechanisms between patients with CRSsNP and
those with CRSwNP and even within a clinical phenotype,
suggesting the presence of endotypes.6-8 However, these
distinctions between patients with CRSsNP and those with
CRSwNP might not be universal and have not been studied on a
worldwide scale.9-11 Differences between white and Chinese
patients with CRS (eg, in terms of the frequency of comorbid
asthma; the bacterial patterns isolated from the nose, including
Staphylococcus aureus; and other observations) suggest that there
might indeed be differences of CRS endotypes in different regions
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that the eosinophilic subtype within CRSwNP has increased
significantly during the past 10 years in Thailand, together with
an increasing intramucosal presence of S aureus, suggesting
that the prevalence of a specific endotype can change over
time.17 However, another recent report indicated that
second-generation Asian patients with CRSwNP living in the
United States maintained their noneosinophilic inflammation in
CRSwNP status, probably as a consequence of their genetic
background.18
Previous studies have focused on the TH cell endotypes of CRS in
different regions of Europe, Asia, and Australia. Zhang et al13
compared the eosinophilic and neutrophilic inflammation patterns
and T-cell patterns between European and southern Chinese
patients with CRSwNP and showed that there was more TH2 bias
with higher GATA-3 and IL-5 levels, together with more
eosinophilic inflammation, in European patients, whereas more
neutrophilic inflammationandendotypeswithTH1/TH17were found
in southern Chinese patients with CRSwNP. Cao et al15 found that
patients with CRSsNP from central China to have a predominantly
TH1 pattern, similar to that demonstrated in European patients
with CRSsNP,8 whereas patients with eosinophilic CRSwNP had a
TH2-biased inflammation accompanied by TH17 reactions.
A recent study from Japan has shown that the contemporary cytokine
profiles in Tochigiese patientswithCRSsNP/CRSwNPare similar to
those of European patients with CRS.11
In view of these findings, it is tempting to hypothesize that apart
from genetic factors, diversity in geographic and climatic
conditions might influence the immunologic patterns of disease
in subjects living in different regions within a single country or in
different countries. Thus in the present studywe aimed to evaluate
the endotypes of patients with CRS from 2 European regions,
Benelux (Belgium, Netherland, and Luxembourg) and Berlin,
Germany; 2 Chinese regions, Beijing in northern China and
Chengdu in the Sichuan province of southwestern China; and 1
region each in Japan (Tochigi) and Australia (Adelaide) based on
TH cytokines and related immune factors.METHODS
Patients
A total of 573 subjects, including patients with CRSsNP, patients with
CRSwNP, and control subjects, were enrolled in this study consecutively over
a specific period from Benelux and Berlin (European regions: 197 patients),
Adelaide (Australian region: 68 patients), Beijing and Chengdu (Chinese
regions: 266 patients), and Tochigi (Japanese region: 42 patients; Fig 1). The
general information of subjects from the 6 regions is shown in Table I.
Diagnoses of CRS were based on patients’ histories, clinical examinations,
nasal endoscopies, and computed tomographic scans of the sinuses in
accordance with the ‘‘European position paper on rhinosinusitis and nasal
polyps 2012’’ guidelines.1 Patients without any sinonasal disease whopresented for septoplasty for anatomic variations were recruited as control
subjects from each region. Atopic status was evaluated by detecting IgE
antibodies against various common inhalant allergens with the Phadiotop
test (Phadia, Uppsala, Sweden) and skin prick tests. Diagnoses of asthma
and aspirin sensitivity were made by pulmonologists based on lung function
and challenge tests. None of the subjects used oral or nasal corticosteroids
4 weeks before or antibiotics 2 weeks before their surgeries.
The ethics committees of Ghent University Hospital, the Academic
Medical Centre of Amsterdam, University Hospital Leuven, Charite Berlin,
Beijing TongRen Hospital, Huaxi Hospital of Sichuan University, the
University of Adelaide, and Flinders University of Adelaide and the local
ethics committee of the JichiMedical University Hospital of Tochigi approved
the study. All patients provided written informed consent.
Measurement of cytokine and IgE levels in tissue
homogenates
All samples were obtained by using the same procedures in the different
centers, following collaborations between the centers and the Upper Airways
Research Laboratory at Ghent University, as described previously.10-12 Samples
from nasal polyps (NPs) of patients with CRSwNP, ethmoidal mucosa of patients
with CRSsNP, and inferior turbinate mucosa of control subjects were processed
and analyzed in 2 laboratories, with the laboratory in Ghent University Hospital
handling all the samples from Benelux, Berlin, Adelaide, and Tochigi, and the
laboratory in Beijing TongRen Hospital handling the samples from Beijing and
Chengdu. Briefly, freshly obtained tissue specimens were homogenized, as previ-
ously described,13 and assayed for IL-5, IFN-g, IL-17A, IL-8, TGF-b1, andMPO
by using commercially available ELISA kits (Quantikine ELISA, R&D Systems,
Minneapolis,Minn;MPO,Oxis International, Portland,Ore).Mucosal tissue total
IgE, ECP, and specific IgE levels to S aureus enterotoxins (SEs)weremeasured by
using the UniCAP system (Pharmacia, Uppsala, Sweden). Twelve random and
blinded NP samples from patients in Belgium were analyzed for IL-5, IL-17,
IL-8, and ECP in both laboratories in Belgium and Beijing by using the
same brand of ELISA kits (Quantikine ELISA, R&D Systems) to
ensure comparability of measurements in the 2 laboratories. Expression of TH1,
TH2, and TH17 marker cytokines, such as IFN-g, IL-5, and IL-17, were used to
define the inflammatory profiles. When a sample showed protein expression for
2 or 3 of those markers, it was considered double/triple positive.Comparison of eosinophilic versus noneosinophilic
CRSwNP
Eosinophilic and noneosinophilic CRSwNP were defined based on the
ECP/MPO ratio, with a ratio of greater than 1 being eosinophilic and a ratio of
less than 1 being noneosinophilic/neutrophilic disease.8Statistics
Results were analyzed with SPSS 17.0 software (SPSS, Chicago, Ill). Data
were entered as both continuous and categorical variables (less than or greater
than the detection limit).
Positivity was defined as the percentage of positive samples expressing a
certainmarker or expressing amarker above a certain cutoff value. Because all
the values for ECP, IL-8, and tissue total IgE were greater than the detection
limit, receiver operating characteristic curve analysis was used to obtain cutoff
values that could best discriminate between CRSsNP and CRSwNP. Because
data were found to be nonparametric, medians and interquartile ranges were
reported. The x2 or Fisher exact test was used for categorical data, with a
2-tailed Kruskal-Wallis test followed by a Mann-Whitney U test used for
analysis of ordinal data. Paired-samples tests and Pearson correlation analysis
were used to compare the results of the same parameters measured in the 2
laboratories for the same samples. Finally, multiple correspondence analyses
(MCA)were performed to present the pattern of relationships among the 3 phe-
notypes (patients with CRSwNP, patients with CRSsNP, and control subjects),
the key TH2/TH17/TH1 cytokines (IL-5, IL-17, and IFN-g), and the world
regions. Bonferroni corrections were applied for the analysis of multiple com-
parators, and P values of .05 or less were considered statistically significant.
FIG 1. World map with locations of the 6 centers and numbers of patients included in the study.
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Patients’ characteristics
Table I shows the demographic and clinical characteristics of
the subjects. The proportion of male subjects was higher than
that of female subjects in all 3 groups in the 6 regions. Positive
skin prick test responses were more frequent in patients with
CRSwNP than in patients with CRSsNP and control subjects
in Beijing only. The prevalence of asthma in patients with
CRSwNP in Beijing and Chengdu was lower than that of the
other 4 regions.Comparability of measurements
Assessment of the consistency of measurements between the 2
laboratories measuring all samples, Ghent and Beijing, as
determined by using 12 randomly selected samples, which had
previously been analyzed in Ghent for IL-5, IL-17, IL-8, and
ECP, demonstrated high consistency between the 2 laboratories
(Table II).Multiple correspondence analyses for the
interrelationships between phenotypes and
TH1/TH2/TH17 cytokines
Fig 2 shows the multiple correspondence analyses per-
formed to demonstrate the relationships between CRSwNP,
CRSsNP, and control phenotypes and positive/negative IL-5,
IL-17, and IFN-g expressions and for the CRSwNP
phenotype among the 6 regions. The CRSwNP phenotype
was located near IL-5 positivity, whereas the CRSsNP
phenotype was situated close to IL-17 and IFN-g positivity
(Fig 2, A). In contrast, the control phenotype was situated
near IL-5, IL-17, and IFN-g negativity (Fig 2, A).
Assessment of the CRSwNP phenotype by region indicated
that in Adelaide, Benelux, Berlin, and Tochigi this phenotype
was near IL-5 positivity and IL-17 and IFN-g negativity. In
contrast, the CRSwNP phenotype in Beijing was closer to
IL-17 and IFN-g positivity and near IL-5 positivity (Fig 2,
B), whereas in Chengdu this phenotype was near to the
negativities of these 3 cytokines (Fig 2, B).
TABLE I. Demographic and clinical characteristics of the subjects in the 6 study regions
No. Sex (female/male) Age (y), median (range) Allergy, no. (%) Asthma, no. (%) Prior surgery, no. (%)
Benelux
Control subjects 35 13/22 29.0 (17.3-69.3) 8 (22.86) 4 (11.43) 1 (2.86)
Patients with CRSsNP 45 20/25 43.1 (16.8-69.9) 19 (42.22) 6 (13.33) 10 (22.22)
Patients with CRSwNP 45 13/32 46.5 (24.8-71.6) 20 (44.44) 20 (44.44) 22 (48.89)
P value — NS <.001 NS <.001 <.001
Berlin
Control subjects 23 9/14 26.9 (18.2-59.9) 10 (43.48) 2 (8.70) 0
Patients with CRSsNP 38 15/23 37.8 (19.4-58.0) 23 (60.53) 4 (10.53) 0
Patients with CRSwNP 11 4/7 42.6 (28.0-53.1) 6 (54.55) 4 (36.36) 0
P value — NS .013 NS NS —
Adelaide
Control subjects 15 8/7 54.0 (46.0-63.0) — — —
Patients with CRSsNP 20 — 59.0 (48.0-68.0) 11 (55.00) 9 (45.00) —
Patients with CRSwNP 33 — 55.0 (47.0-58.0) 19 (57.58) 14 (42.42) —
P value — — — NS NS —
Beijing
Control subjects 24 13/11 39.5 (17.0-68.0) 1 (4.17) 0 0
Patients with CRSsNP 33 28/5 47.0 (13.0-72.0) 8 (24.24) 1 (3.03) 0
Patients with CRSwNP 95 75/20 47.0 (14.0-78.0) 35 (36.84) 13 (13.68) 29 (30.53)
P value — .017 NS .006 .05 —
Chengdu
Control subjects 24 7/17 31.5 (17.0-60.0) 5 (20.83) 1 (4.17) —
Patients with CRSsNP 21 9/12 51.0 (16.0-59.0) 8 (38.10) 0 —
Patients with CRSwNP 69 27/42 37.0 (17.0-66.0) 24 (34.78) 5 (7.25) —
P value — NS NS NS NS —
Tochigi
Control subjects 17 1/16 60.0 (19.0-80.0) 7 (41.18) 0 —
Patients with CRSsNP 7 4/3 57.0 (29.0-71.0) 2 (28.57) 0 —
Patients with CRSwNP 18 4/14 56.5 (17.0-71.0) 6 (33.33) 6 (33.33) —
P value — .020 NS NS .010 —
P value for all — <.001 <.001 .006 <.001 —
NS, Not significant.
J ALLERGY CLIN IMMUNOL
VOLUME 138, NUMBER 5
WANG ET AL 1347Comparison of IL-5, IL-17, and IFN-g in patients
from different regions
Concentrations of IL-5, IL-17, and IFN-g in samples of the 3
patient groups from the different regions are shown in Fig 3.
Assessment of IL-5 showed that the IL-5 concentrations in
patients with CRSwNP were significantly higher than those of
patients with CRSsNP and control subjects from Benelux, Berlin,
Adelaide, Beijing, and Tochigi, with Chengdu as the exception
(Fig 3, A, and see Tables E1.1 and E1.2 in this article’s Online
Repository at www.jacionline.org). Similarly, assessment of
IL-17 showed that interleukin concentrations in the CRSwNP
groups were significantly higher than those of the CRSsNP
and control groups in Adelaide and Beijing, whereas the
concentration of IL-17 in the CRSsNP group was much
higher than that in the CRSwNP and control groups in Tochigi
(Fig 3, B, and see Tables E2.1 and E2.2 in this article’s Online
Repository at www.jacionline.org). In contrast, concentrations
of IFN-g in the samples from the CRSsNP group were
significantly higher than in the CRSwNP and control groups in
Beijing but not significantly different among the 3 groups in the
other 5 regions (Fig 3, C, and see Tables E3.1 and E3.2 in this
article’s Online Repository at www.jacionline.org).
Assessment for IL-5, IL-17, and IFN-g positivity indicated that
these were significantly different among the CRSwNP, CRSsNP,
and control groups in the 6 regions (data are shown as Fig E1 and
Tables E1.3, E1.4, E2.3, E2.4, E3.3 and E3.4 in this article’s
Online Repository at www.jacionline.org).Fig 4 shows the TH1/TH2/TH17 cytokine expression in the
patients with CRSwNP in the different regions. Between 46%
and 82% of the patients with CRSwNP from Benelux, Berlin,
Adelaide, and Tochigi were solely IL-5 dominant, with patients
from Europe (Benelux and Berlin) showing the highest IL-5
dominance. Assessment of total IL-5 positivity in these 4 regions
showed that this ranged from 58% in Tochigi to 83% in Benelux.
Although patients with CRSwNP from China (Beijing and
Chengdu) demonstrated much lower single IL-5 dominance,
ranging between 16% and 19%, the total IL-5 positivity of 61%
in the CRSwNP group from Beijing was similar to that of patients
in Benelux, Berlin, Adelaide, and Tochigi and comprised mainly
TH2/TH1 and TH2/TH17mixed patterns. In contrast, the CRSwNP
group from Chengdu showed a lower TH2 pattern, with 20% of
total positivity of IL-5 and 23% of total positivity of comprised
of TH17 and TH1 patterns.
As shown in Fig 5, in patients with CRSsNP, the total IL-5
positivity of patients in Benelux, Berlin, Beijing, and Adelaide
ranged from 33% in Benelux to 40% in Adelaide, and single
IL-5 positivity in Benelux, Berlin, Adelaide, and Beijing
ranged from 3% for Beijing to 32% for Berlin. However,
the total IL-5 positivity of the CRSsNP groups from Chengdu
and Tochigi were only 5% and 16% (12% of individual IL-5
positivity), respectively. The total positivity of TH1 and TH17
cytokines without IL-5 expression among the 6 regions ranged
from 13% and 14% in Tochigi and Chengdu to 58% in
Beijing.
TABLE II. Consistency in analysis of mediators in randomly selected samples (n 5 12) from laboratories in Ghent and Beijing
Ghent, mean 6 SEM Beijing, mean 6 SEM Paired differences, mean 6 SEM t P value* r P valuey
IL-5 (pg/mL) 270.30 6 126.42 291.72 6 110.63 21.42 6 31.98 0.670 .517 0.972 <.01
IL-17 (pg/mL) 55.51 6 26.28 61.00 6 30.33 5.49 6 7.97 0.689 .505 0.971 <.01
IL-8 (pg/mL) 11,769.26 6 3,157.35 12,925.55 6 3,327.93 1,156.29 6 816.57 1.416 .184 0.970 <.01
ECP (mg/L) 8,024.68 6 1,348.69 9,199.93 6 1,521.15 1,175.25 6 800.95 1.467 .170 0.851 <.01
*Paired-samples t test.
All P values of correlations.
FIG 2. Multiple correspondence analyses plot for the interrelationships between CRSwNP, CRSsNP, and
control phenotypes and positive/negative protein expressions for the cytokines IL-5, IL-17, and IFN-g (all
regionsA); and interrelationships between the 6 regions and IL-5, IL-17 and IFN-g protein expressions for the
CRSwNP phenotype (B). Distance between variables (phenotype and cytokine or region and cytokine)
indicates the approximate relationship between variables. Thus the nearer they are located together, the
stronger the relationship.
J ALLERGY CLIN IMMUNOL
NOVEMBER 2016
1348 WANG ET ALMarker of eosinophilic (ECP) and neutrophilic (IL-8)
inflammation
The control, CRSsNP, and CRSwNP groups all displayed
generally high levels of ECP (Fig 3, D, and see Tables E4.1 and
E4.2 in this article’s Online Repository at www.jacionline.org).
However, the concentration of ECP in the CRSwNP groups
from Benelux, Adelaide, and Tochigi were higher than those in
Chengdu, and the concentrations of ECP in Berlin and Beijing
were higher than that of Chengdu, although these did not attain
statistical significance. Because there were significant differences
in ECP levels between the control and CRSwNP groups among
the 6 regions, we defined a cutoff value of greater than
1189.10 mg/L that discriminated patients with NPs from control
subjects. In this regard all 6 regions exhibited eosinophilic
NPs in more than 60% (data are shown in Fig E1, D, and
supplementary Tables E4.3 and E4.4).
IL-8 concentrations were significantly higher in patients
with CRSwNP compared with the CRSsNP and control
groups in Benelux, Berlin, Beijing, and Chengdu but not in
Tochigi (no IL-8 data were available for Adelaide), with
concentrations of IL-8 in patients with CRSwNP from Beijing
being much higher than those in Benelux, Berlin, and
Chengdu (Fig 3, E, and see Tables E5.1 and E5.2 in this article’s
Online Repository at www.jacionline.org). IL-8 positivity was
also found to be significantly higher in the CRSsNP and
CRSwNP groups compared with control subjects in all
regions, with the highest percentage of IL-81 samples being noted
in Beijing (data are shown as Fig E1,E, and Tables E5.3 and E5.4).Tissue total IgE and specific IgE to SEs
Tissue total IgE levels were generally found to be higher in the
CRSwNP groups compared with the CRSsNP and control groups
in the 6 study regions (Fig 3, F). Furthermore, concentrations of
tissue total IgE in patients with CRSwNP from Adelaide
and Tochigi were comparatively higher than in other regions
(Fig 1, F, and see Tables E6.1 and E6.2 in this article’s Online
Repository at www.jacionline.org), and around 80% of the
patients from Adelaide and Tochigi had total IgE levels
greater than cutoff values compared with around 50% to 60%
of patients from the other regions (data are shown as Fig E1, F,
and Tables E6.3 and E6.4).
Fig 6 shows the percentage of samples positive for SE-specific
IgE in the NP tissue of patients with CRSwNP in Benelux,
Adelaide, Beijing, Chengdu, and Tochigi and illustrates that
SE-specific IgE was found in significantly greater numbers of
patients from Adelaide and Tochigi and in significantly lower
numbers of patients from Beijing and Chengdu compared with
patients from other regions. Data for SE-specific IgE were not
available for samples from Berlin.Eosinophilic and noneosinophilic (neutrophilic)
dominant endotypes of CRS
We used the ECP/MPO ratio (>1, eosinophilic; <1, neutro-
philic) to evaluate the predominantly eosinophilic or neutrophilic
patterns of the CRSwNP, CRSsNP, and control groups among the
6 regions (Fig 7 and Tables E7.1 and E7.2 in this article’s Online
FIG 3. Concentrations of IL-5 (A), IL-17 (B), IFN-g (C), ECP (D), IL-8 (E), and tissue total IgE (F) in control
subjects, patients with CRSsNP, and patients with CRSwNP. Data were not available for IL-8 in samples
from patients in Adelaide.
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Greater than 50% of patients with CRSwNP in Benelux, Berlin,
Adelaide, and Tochigi demonstrated a predominantly eosino-
philic endotype compared with less than 30% patients in Beijing
and Chengdu. In contrast, the majority of subjects in the CRSsNP
and control groups demonstrated a predominantly neutrophilic
endotype in all regions. The eosinophilic endotypes were
significantly more frequent in patients with CRSwNP than in
patients with CRSsNP in Benelux, Berlin, and Adelaide and
also compared with patients with CRSwNP in Beijing, Chengdu,
and Tochigi (data are shown as Tables E8.1 and E8.2 in this
article’s Online Repository at www.jacionline.org).TGF-b1
Concentrations of TGF-b1 were significantly higher in the
CRSsNP groups than the CRSwNP groups in Benelux, Berlin,
and Chengdu (data are shown as Tables E9.1 and E9.2 in this
article’s Online Repository at www.jacionline.org). Concentra-
tions of TGF-b1 in the control and CRSwNP groups from Tochigi
were significantly higher than all other regions.DISCUSSION
In the present study we compared TH2/TH1/TH17 cytokine
patterns and markers of eosinophilic and neutrophilic inflamma-
tion in patients with CRS from 6 regions covering Europe, Asia,
and Australia. To our knowledge, this is the first study to evaluate
the diversity of immunologic endotypes of CRS among Europe,
Asia, and Australia based on TH cytokines and related markers
in a multicenter approach.In white patients a TH2-dominant pattern has generally been
considered the main immunologic signature of CRSwNP,
whereas CRSsNP displays a TH1-dominant pattern.
8 Studies
comparing European patients with CRSwNP and southern
Chinese patients with CRSwNP with regard to inflammation
have further shown that European patients present with a TH2
bias with eosinophilic inflammation, whereas their southern Chi-
nese counterparts often present with a TH1/TH17 polarization
with neutrophilic inflammation.13 Based on the ECP/MPO ratio,
we also found a higher percentage of the eosinophil-dominant
endotype of CRSwNP in Benelux, Berlin, Adelaide, and Tochigi
than in Beijing and Chengdu, thus suggesting the presence of
important immunologic differences between European and
Chinese patients with CRS. However, these findings raise the
possibility that diverse immunologic endotypes can also be
prevalent among subjects of similar ethnicity from different
national and international regions as a consequence of
environmental differences.
In accordance with findings of previous studies,8,13 the present
study confirmed that CRSwNP is related to IL-5, representing a
TH2 cytokine, whereas CRSsNP relates to TH1/TH17 as a general
pattern for the 6 regions in the MCA. White patients with
CRSwNP showed a relatively stronger TH2 pattern, whereas
Chinese patients with CRSwNP from Beijing showed mixed
TH2/TH1/TH17 patterns, and patients with CRSwNP from
Chengdu showed very low IL-5 positivity. Interestingly, Japanese
patients with CRSwNP had higher individual TH2 patterns than
subjects from Beijing but lower patterns than white patients
with CRSwNP. In line with the positivity of IL-5, concentrations
of IL-5 also showed similar diversity among the 6 regions for
CRSwNP. The above results suggest that patients with CRS
FIG 4. Patterns of TH1/TH2/TH17 cytokine expression in samples from patients with CRSwNP: Benelux
(A), Berlin (B), Adelaide (C), Beijing (D), Chengdu (E), and Tochigi (F).
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TH2-mediated disease than patients with CRS from European
regions, possibly because of a combination of both genetic and
environmental factors. The distributing patterns of the endotypes
based on key cytokines might be crucial for an individualized
therapeutic strategy because one previous studywith a humanized
anti-human IL-5 mAb has demonstrated that this therapy was
effective in reducing the size of NPs in only half of the patients
with CRSwNP.19
Although the CRSsNP phenotype has generally been
considered TH1 dominant, with higher levels of IFN-g in white
and Chinese subjects with CRS,8,15 the present study showed
that only the patients with CRSsNP from Beijing had higher
IFN-g levels compared with patients with CRSwNP and control
subjects. Similarly, the patients with CRSsNP from Benelux
had higher IFN-g levels compared with those in control subjects.
Moreover, the TH1/TH2/TH17 patterns of CRSsNP also showed
diversity with 33% to 40% positivity of IL-5 in patients from
Benelux, Berlin, Adelaide, and Beijing but only 5% IL-5
positivity in patients from Chengdu. Thus the present study
indicates a need for consideration of individualized therapeutic
strategies for patients with CRSsNP rather than standardized
therapy with steroids and antibiotics.1
Inflammation and remodeling are 2 aspects of CRS; however,
whether these 2 aspects are related or dissociated still needs to be
elucidated.20-22 In the present study we found an interestingendotype for CRSwNP and CRSsNP. With regard to pannegativ-
ity of TH1/TH2/TH17 in all 6 study regions, particularly in
Chengdu, 57% of patients with CRSwNP and 81% of patients
with CRSsNP demonstrated this endotype, indicating that
the vast majority of patients with CRSwNP and those with
CRSsNP in Chengdu were independent of TH1/TH2/TH17
endotype–mediated reactions. However, in view of a lack of
any specific pattern among the different regions for TGF-b1,
the delegating factor of remodeling, the present study suggests
that inflammation based on TH immunity is unlikely to rationally
explain remodeling in patients with CRS.
S aureus can contribute to TH2 differentiation and amplify
the inflammation.23 Indeed, one recent study has demonstrated
that a shift from predominantly neutrophilic to eosinophilic
CRSwNP over time, accompanied by an increase in levels of
various inflammatory markers, including IgE, was associated
with an increase in the intramucosal presence of S aureus.17
Specific IgE against SE has also been shown to act as an
independent risk factor for asthma,24 with relatively higher
IL-5, ECP, SE-specific IgE, and tissue total IgE levels
increasing the risk of comorbid asthma and IFN-g playing a
protective role.12 The present study demonstrated higher total
tissue IgE levels from Adelaide and Tochigi compared with
Beijing and Chengdu, as well as higher positivity of
SE-specific IgE from Benelux, Adelaide, and Tochigi
compared with Beijing and Chengdu. These immunologic
FIG 5. Patterns of TH1/TH2/TH17 cytokine expression in samples from patients with CRSsNP (only 7 cases of
CRSsNP in Tochigi, data not shown): Benelux (A), Berlin (B), Adelaide (C), Beijing (D), and Chengdu (E).
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levels, and lack of SE-specific IgE in tissue might explain
the lower comorbidity of asthma and atopy in Chinese subjects
when compared with white and Japanese subjects. It can be
speculated that although the IL-5 positivity in patients from
Beijing with CRSwNP was much higher than that in patients
from Chengdu, the higher IFN-g positivity might inhibit the
subjects from having asthma, resulting in the approximately
similar prevalence of asthma noted in patients with CRSwNP
in Beijing and Chengdu. It has also been shown that certain
specific patterns of microbiota would be related to a TH17
polarization or an eosinophilic endotype of CRSwNP.25,26
Similarly, air pollution, specifically particulate matter (parti-
culate matter with a diameter <10 mm and smaller), might
potentially enhance TH17 polarization through activation of
the aryl hydrocarbon receptor,27 suggesting that the diversity
of environmental factors, such as microbiota and air pollution,
can result in differences in TH patterns among the 6 regions to
some degree, although this needs to be defined further.
Recently, Mahdavinia et al18 reported that second-generation
Asian American patients with CRSwNP demonstrated lowerlevels of tissue eosinophilia than their white American
counterparts and suggested that this was mainly due to genetic
factors. However, only 11 second-generation Asian Americans
with very diverse genetic backgrounds were included, and
therefore the authors’ interpretation might be questioned. In
contrast, the demonstration that tissue eosinophilia in NPs can
dramatically increase over a period of 10 to 20 years in the
same study cohorts17,28 provides support for the involvement of
environmental factors, such as air pollution, the microbiome,
and also use of antibiotics, in mucosal inflammatory patterns in
patients with CRS.
In the present study IL-8 levels and positivity appeared to be
upregulated in the CRSwNP groups from all 6 regions, with the
highest levels seen in Beijing. Interestingly, the IL-8 level of the
control group from Beijing was also much higher than that of the
other 5 regions. Because IL-8 synthesis has been shown to be
induced by air pollution,29 it is possible that the high levels of IL-8
seen in both patients with CRS and control subjects might be the
result of air pollution in Beijing, which has increased significantly
in recent years, although further studies are needed to validate
this.
FIG 7. Percentage of the samples with eosinophilic (ECP/MPO ratio >1) and
noneosinophilic (ECP/MPO ratio <1) phenotypes.
FIG 6. Percentages of positive samples for tissue-specific IgE to SEs in
patients with CRSwNP in different regions. nP 5 .001 and *P < .001). Data
were not available for SE-specific IgE in samples from patients in Berlin.
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patients with CRSwNP and those with CRSsNP, the present study
has demonstrated that there appears to be an extreme diversity in
terms of the mucosal immunologic endotypes of CRS in Europe,
China, Japan, and Australia. However, these findings are
somewhat limited by the shortcomings of this study and need to
be confirmed in other studies investigating greater numbers of
patients from specific environments. In particular, although the
samples of this study were randomly selected, this is not a
prevalence study and cannot completely represent the populations
of these regions. Although analysis of samples in 2 laboratories
demonstrated accordance between the 2 laboratories, it would
be desirable to further harmonize sampling and measurement
techniques. Despite these shortcomings, the present study
provides important insights into the diversity of diseases of
what was believed to be one umbrella term, CRS, and provides
important pointers toward assessing the mechanisms underlying
different endotypes of patients with CRS.30 Furthermore, this
study highlights the need for future observations on the change
in immune patterns over time in patients with airway disease
and the consequences thereof in terms of prognosis and
management.
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Clinical implications: The cytokine and inflammatory marker
profiles of CRS show diversity among European, Asian, and
Oceanian patients, suggesting the need for individualized ther-
apeutic strategies.REFERENCES
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